1. Background
2. Objectives
3. Materials and Methods
3.1. Bacterial Material
| Constituents | Retention Time, min | Compositions, % | KI |
|---|---|---|---|
| δ-2-carene | 9.6 | 6.8 | 1002 |
| 1, 8-cineole | 10.6 | 7.0 | 1031 |
| Trans-caryophyllene | 30.9 | 9.2 | 1409 |
| Aromadendrene | 31.8 | 2.7 | 1441 |
| α-humulene | 32.7 | 2.2 | 1455 |
| Germacrene-D | 34.0 | 3.8 | 1482 |
| Ledene | 34.5 | 5.4 | 1485 |
| Valencen | 34.8 | 1.5 | 1496 |
| Torreiol | 42,8 | 2.6 | 1645 |
| α-eudesmol | 43.4 | 3.7 | 1654 |
| Bicyclogermacrene | 35.8 | 10.6 | 1500 |
| β- guaiene | 36.0 | 2.4 | 1503 |
| δ-cadinene | 36.8 | 3.1 | 1523 |
| Epiglobulol | 37.0 | 2.3 | 1564 |
| Cariophyllene oxide | 39.0 | 7.4 | 1583 |
| Globulol | 39.2 | 2.1 | 1585 |
| δ- guaiane | 39.6 | 2.4 | 1596 |
| Guaiol | 39.8 | 3.3 | 1601 |
| 10-epi-α-eudesmol | 41.5 | 1.3 | 1624 |
| Terpinolene | 12.9 | 1.6 | 1089 |
| Camphor | 16.3 | 2.6 | 1146 |
| Total | 84.0 |
aAbbreviation: KI, Kovats retention index
3.2. Plant Material and Isolation of Essential Oils
3.3. Gas Chromatography–Mass Spectrometry Analysis
3.4. Antibacterial Test (Minimal Inhibitory Concentration)
| Bacteria | Source | Antibiotic Resistance |
|---|---|---|
| Escherichia coli EC27 | surgical wound | Ast, Ax, Amp, Ami, Amox, Ca, Cfc, Cf, Caz, Cip, Clo, Im, Can, Szt, Tet, Tob |
| Staphylococcus aureus SA358 | surgical wound | Oxa, Gen, Tob, Ami, Can, Neo, Para, But, Sis, Net |
aAbbreviation: Ast, aztreonam; Ax, amoxicillin; Amp, ampicillin; Ami, amikacin; Amox, amoxicillin; Ca, cefadroxil; Cfc, cefaclor; Cf, cefalotin; Caz, ceftazidime; Cip, ciprofloxacin; Chlo, chloramphenicol; Im, imipenem; Kan, kanamycin; Szt, sulfametim; Tet, tetracyclin; Tob, tobramycin; Oxa, oxacillin; Gen, gentamicin; Neo, neomycin; Para,paramomycin; But, butirosin; Sis, sisomicin; Net, netilmicin.
3.5. Modulation of Antibiotic Activity by Direct Contact
3.6. Determination of Minimal Inhibitory Dose (MID) of Essential Oil by Gaseous Contact
3.7. Antibiotic Modifying Activity by Gaseous Contact
3.8. Statistical Analysis
4. Results
4.1. Chemical Composition of the Essential Oil
4.2. Antimicrobial Activity
| Bacterial | E. coli, (EC27) | E. coli, (ATCC2592) | S. aureus, (SA358) | S. aureus, (ATCC1269) | B. cereu, (ATCC33018) | P. aeruginosa, (ATCC15442) |
|---|---|---|---|---|---|---|
| EOHm | 64 | 512 | ≥ 1024 | 512 | 256 | 512 |
| Amikacin | 64 | 256 | 256 | 256 | 128 | 128 |
| Neomycin | 32 | 256 | 128 | 128 | 256 | 64 |
| Gentamicin | 16 | 64 | 64 | 64 | 256 | 64 |
| Kanamycin | 16 | 256 | 128 | 64 | 256 | 128 |
4.3. Modulatory Bacterial Resistance Effect
| Bacteria | AMI | GENT | NEO | KAN | ||||
|---|---|---|---|---|---|---|---|---|
| OE | CONT | OE | CONT | OE | CONT | OE | CONT | |
| E. coli ATCC25922 | 32 | 32 | 64 | 64 | 64 | 16 | 64 | 64 |
| E. coli 27 | 32 | 32 | 64 | 64 | 16 | 16 | 32 | 32 |
| S. aureus ATCC12692 | 128 | 128 | 64 | 64 | 128 | 16 | 128 | 128 |
| S. aureus 358 | 256 | 4 | 128 | 64 | 512 | 16 | 128 | 16 |
| P. aeruginosa ATCC15442 | 64 | 16 | 512 | 512 | 32 | 32 | 128 | 128 |
| B. cereus ATCC33018 | 32 | 32 | 64 | 64 | 16 | 16 | 64 | 64 |
aAbbreviations: AMI, amikacin; GENT, gentamycin; NEO, neomycin; KAN, kanamycin; OE, essencial oil; CONT, negative control (aminoglycoside only).
| Antibiotic | N. TRA | DMSO | EOHm, 50% | EOHm, 25% | EOHm, 12% | EOHm, 6% |
|---|---|---|---|---|---|---|
| S. aureus, ATCC12692 | ||||||
| Control GENT | 16.3 ± 0.6 | 16.7 ± 0.6 | 60.0 ± 0.5 a | 60.1 ± 0.6 a | 16.3 ± 0.8 | 16.3 ± 0.5 |
| Increase, % | - | - | 268.1 | 268.7 | - | - |
| Control AMI | 17.3 ± 0.6 | 17.3 ± 0.6 | 74.2 ± 0.0 a | 47.0 ± 0.5 a | 17.3 ± 0.7 | 17.3 ± 0.0 |
| Increase, % | - | - | 328.9 | 171.7 | - | - |
| Control TOBRA | 15 ± 0.7 | 15.3 ± 0.7 | 57 ± 0.3 a | 34 ± 0.0 a | 25 ± 0.3 a | 18 ± 0.0 a |
| Increase, % | - | - | 280 | 126.7 | 66.7 | 20 |
| P. aeruginosa, ATCC15442 | ||||||
| Control GENT | 14.3 ± 0.6 | 14 ± 0.0 | 17 ± 0.7 a | 14.3 ± 0.4 | 14.3 ± 0.8 | 14.3±0.0 |
| Increase, % | - | - | 18.9 | - | - | - |
| Control AMI | 15 ± 0.0 | 15.3 ± 0.6 | 24 ± 0.3 a | 15 ± 0.4 | 15.2 ± 0.7 | 15 ± 0.5 |
| Increase, % | - | - | 60 | - | 1.3 | - |
| Control TOBRA | 16 ± 0.0 | 16 ± 0.3 | 18 ± 0.0 b | 17 ± 0.7 | 17 ± 0.7 | 17 ± 0.7 |
| Increase, % | - | - | 12.5 | 6.3 | 6.3 | 6.3 |
| E. coli, 27 | ||||||
| Control GENT | 15 ± 0.0 | 15 ± 0.0 | 21 ± 0.0 a | 17 ± 0.0 a | 15±0.0 | 15±0.0 |
| Increase, % | - | - | 40 | 13.3 | - | - |
| Control AMI | 17 ± 0.7 | 16.5 ± 0.3 | 31 ± 0.0 a | 22 ± 0.0 a | 17 ± 0.0 | 17 ± 0.0 |
| Increase, % | - | - | 82.4 | 29.4 | - | - |
| Control TOBRA | 15±0.7 a | 15 ± 0.0 | 27 ± 0.0 a | 19±0.0 a | 15 ± 0.0 | 15 ± 0.0 |
| Increase, % | - | - | 80 | 26.7 | - | - |
| B. cereus, ATCC33018 | ||||||
| Control GENT | 18 ± 0.3 | 18.3 ± 0.0 | 23 ± 0.0 a | 18 ± 0.0 | 18 ± 0.0 | 18 ± 0.0 |
| Increase, % | - | - | 27.8 | - | - | - |
| Control AMI | 18 ± 0.0 | 18 ± 0.0 | 32 ± 0.0 a | 23 ± 0.0 a | 18 ± 0.0 | 18 ± 0.0 |
| Increase, % | - | - | 77.8 | 27.8 | - | - |
| Control TOBRA | 14 ± 0.0 | 14.5 ± 0.7 | 24 ± 0.0 a | 19 ± 0.3 a | 18 ± 0.0 a | 18 ± 0.0 a |
| Increase, % | - | - | 71.4 | 35.7 | 28.6 | 28.6 |
| S. aureus, 358 | ||||||
| Control GENT | 22.0 ± 0.5 | 22.0 ± 0.5 | 26 ± 0.3 a | 24 ± 0.0 a | 22.0 ± 0.5 | 22.0 ± 0.5 |
| Increase, % | - | - | 18.2 | 9.1 | - | - |
| Control AMI | 25.0 ± 0.5 | 25.0 ± 0.5 | 35 ± 0.5 a | 27 ± 0.4 b | 25.0 ± 0.5 | 25.0 ± 0.5 |
| Increase, % | - | - | 40 | 8 | - | - |
| Control TOBRA | 25.5 ± 0.6 | 25.5 ± 0.6 | 34 ± 0.3 a | 30 ± 0.0 a | 25.5 ± 0.6 | 25.5 ± 0.6 |
| Increase, % | - | - | 33.3 | 17.6 | - | - |
| E. coli, ATCC25922 | ||||||
| Control GENT | 17.0 ± 0.0 | 17.0 ± 0.0 | 20 ± 0.2 a | 19.2 ± 0.2 a | 17.0 ± 0.0 | 17.0 ± 0.0 |
| Increase, % | - | - | 17.6 | 12.9 | - | - |
| Control AMI | 20.5 ± 0.5 | 20.5 ± 0.5 | 21 ± 0.0 | 21 ± 0.0 | 20.5 ± 0.5 | 20.5 ± 0.5 |
| Increase, % | - | - | 2.4 | 2.4 | - | - |
| Control TOBRA | 17.0 ± 0.0 | 17.0 ± 0.0 | 30.0 ± 0.4 b | 28 ± 0.2 a | 17.0 ± 0.0 | 17.0 ±0.0 |
| Increase, % | - | - | 76.5 | 64.7 | - | - |
aAbbreviations: AMI, amikacin; DMSO, dimethyl sulfoxide; GENT, gentamicin; N. TRA, no treated; EOHm, essential oil of H. martiusii; TOBRA, tobramycin.
b Averages following by same letters, in the column, don't differ significantly amongst themselves (a) (n = 3, P < 0.05, test of Tukey). Averages following by different letters, in the line, differ significantly when compared with the respective control, for each microorganism (the n = 3, P < 0,001 ANOVA) and (b) (the n = 3, P < 0.01 ANOVA)
c The results are expressed as Mean + SEM.
